<DOC>
	<DOCNO>NCT01564901</DOCNO>
	<brief_summary>This prospective , observational , multicenter study assess efficacy safety RoActemra/Actemra ( tocilizumab ) use glucocorticoids patient moderate severe rheumatoid arthritis inadequate response previous disease-modifying antirheumatic drug anti-TNF . Data collect 36 week .</brief_summary>
	<brief_title>An Observational Study RoActemra/Actemra ( Tocilizumab ) Patients With Rheumatoid Arthritis Treated With Glucocorticoids</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>Adults patient , 18 year age Patients moderate severe rheumatoid arthritis ( RA ) Patients stable dose prednisone equivalent ( &gt; /=7.5 mg/day ) least 4 week study inclusion Patients previously treat RoActemra/Actemra Any contraindication RoActemra/Actemra</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>